Catalent Pharma Solutions has reached a commercial supply agreement with Palatin Technologies,a Cranbury, New Jersey-based biopharmaceutical company, to support the global commercial product launch of Palatin's bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD).

Bremelanotide, an on-demand, subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. Phase III clinical trials are ongoing, with a commercial launch anticipated in 2018.

The bremelanotide pen devices will be produced at Catalent’s 265,000-square-foot Brussels, Belgium site, the company's flagship sterile fill-finish facility, with a syringe-filling capacity of over 100 million units.

Source: Catalent Pharma Solutions